Meghan Podolsky (@meg-po.bsky.social)

Insurance coverage and type of employment shape inequities in access to semaglutide Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021. https://medicalxpress.com/news/2025-01-coverage-employment-inequities-access-semaglutide.html?utm_source=bsky.app&utm_medium=social&utm_campaign=v2